^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Leiomyosarcoma |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Excerpt:
Summary of recommendations...Eribulin is an option in patients with liposarcomas and LMS [II, A].
DOI:
10.1093/annonc/mdy310
